Suppr超能文献

长期促肾上腺皮质激素治疗婴儿痉挛症的疗效:一项回顾性多中心病例系列研究。

Efficacy of long-term adrenocorticotropic hormone therapy for West syndrome: A retrospective multicenter case series.

机构信息

Department of Child Neurology Comprehensive Epilepsy Center Seirei Hamamatsu General Hospital Hamamatsu Japan.

General Internal Medicine Seirei Hamamatsu General Hospital Hamamatsu Japan.

出版信息

Epilepsia Open. 2021 May 28;6(2):402-412. doi: 10.1002/epi4.12497. eCollection 2021 Jun.

Abstract

OBJECTIVES

Long-term adrenocorticotropic therapy (LT-ACTH), which consisted of 2-4 weeks of daily injections of adrenocorticotropic hormone (ACTH) and subsequent months of weekly injections, was tried for relapsed West syndrome (WS) or other intractable epilepsies in small case reports. Our aim was to explore the efficacy of LT-ACTH for preventing WS relapse, as well as the prevalence of its adverse events.

METHODS

This is a retrospective, nationwide, multicenter case series of patients with WS who underwent LT-ACTH. Clinical information of the patients and protocol of LT-ACTH were collected from participating institutes in this study. We defined clinical response to ACTH as achievement of hypsarrhythmia and epileptic spasms resolution. Patients who responded to daily ACTH injections were identified and assessed whether they experienced WS relapse during/after the weekly ACTH injection period. The outcome was measured by the nonrelapse rate at 24 months after daily ACTH injections using the Kaplan-Meier method.

RESULTS

Clinical information of 16 children with WS was analyzed. The median age at LT-ACTH initiation was 14.5 months (range: 7-68 months). Thirteen (81%) patients had previously undergone conventional ACTH treatment. The LT-ACTH regimens comprised a median of 16 days of daily injections (range: 11-28 days) and 10 months of weekly injections (range: 3-22 months). Seven patients experienced WS relapse during/after subsequent weekly ACTH period, and the nonrelapse rate at 24 months after daily injections was estimated at 60.6% (95% confidence interval: 32.3%-80.0%). Height stagnation, hypertension, and irritability were observed; lethal adverse events were not reported.

SIGNIFICANCE

Our study firstly explored the efficacy of LT-ACTH for preventing WS relapse. LT-ACTH might be a treatment option for patients with relapsed or intractable WS; however, we note that our study is limited by its small sample size and the lack of an appropriate control group.

摘要

目的

长期促肾上腺皮质激素治疗(LT-ACTH)包括 2-4 周的每日肾上腺皮质激素(ACTH)注射和随后几个月的每周注射,曾在小病例报告中尝试用于治疗复发的 West 综合征(WS)或其他难治性癫痫。我们的目的是探讨 LT-ACTH 预防 WS 复发的疗效,以及其不良事件的发生率。

方法

这是一项回顾性的、全国性的、多中心的 WS 患者 LT-ACTH 病例系列研究。从参与本研究的机构收集患者的临床信息和 LT-ACTH 方案。我们将 ACTH 治疗的临床反应定义为高振幅节律障碍和癫痫痉挛的缓解。确定对每日 ACTH 注射有反应的患者,并评估他们在每周 ACTH 注射期间/之后是否出现 WS 复发。使用 Kaplan-Meier 方法测量 24 个月后每日 ACTH 注射后无复发率作为结局。

结果

分析了 16 例 WS 患儿的临床资料。LT-ACTH 开始的中位年龄为 14.5 个月(范围:7-68 个月)。13 例(81%)患儿曾接受过常规 ACTH 治疗。LT-ACTH 方案包括 16 天的每日注射(范围:11-28 天)和 10 个月的每周注射(范围:3-22 个月)。7 例患者在随后的每周 ACTH 期间/之后出现 WS 复发,每日注射后 24 个月的无复发率估计为 60.6%(95%置信区间:32.3%-80.0%)。观察到身高停滞、高血压和易怒;没有报告致命的不良事件。

意义

本研究首次探讨了 LT-ACTH 预防 WS 复发的疗效。LT-ACTH 可能是治疗复发或难治性 WS 的一种选择;然而,我们注意到,我们的研究受到样本量小和缺乏适当对照组的限制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/299a/8166796/b5bb1a40e0a8/EPI4-6-402-g002.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验